invest in digital currency- Top People searches

The daily limit of the construction industry today is that CICC Fortune Beijing Jianguomenwai Street sold 455 million yuan, and the daily limit of the construction industry today was 2.004 billion yuan, with a turnover rate of 22.05%. After-hours data show that the special seats of Shenzhen Stock Connect bought 40.1869 million yuan and sold 19.4816 million yuan, CICC Fortune Beijing Jianguomenwai Street sold 455 million yuan and the special seats of one institution sold 26.1536 million yuan.Morgan Asset Management: In 2025, there are sufficient reasons to continue to over-allocate US stocks. Sylvia Sheng, global multi-asset strategist of Morgan Asset Management, said that there are sufficient reasons to continue to over-allocate US stocks and increase exposure to small and medium-sized stocks. She pointed out that although the valuation may look high, it is expected that the profit growth of S&P 500 companies will continue. Sheng wrote that it is estimated that in 2025, the contribution of the six giants in the S&P 500 index to the profit growth of the other 494 stocks will be the same, and the profit growth of these six giants is expected to slow down from 40% in 2024 to 22%. In the international market, Morgan Asset Management continues to over-allocate Japanese stocks, and its quantitative model shows that the yield of Japanese stocks is attractive and the bottom-up profitability is strong.Zhongzhou Special Materials: Shareholders have transferred and reduced their shares by more than 1%. Zhongzhou Special Materials announced that shareholders holding more than 5% have transferred their shares internally and reduced their shares by more than 1%. After the shareholder completed the internal transfer among the concerted parties, its shareholding ratio changed accordingly. At the same time, the shareholder reduced his shares through the secondary market, and the reduction ratio exceeded 1%. This share change is mainly for the adjustment of shareholding within the company's shareholders, and will not have a significant impact on the company's governance structure and daily operations.

Syrian opposition forces claimed to have taken control of the eastern Syrian city of Deir ez-Zor. According to Al Jazeera and Arabiya TV, on the 10th local time, Hassan Abdel Ghani, commander of Syrian opposition forces, said that "the eastern Syrian city of Deir ez-Zor has been completely controlled".Monetary policy has turned to "moderate easing", and experts say that it is expected to make greater efforts to lower the RRR and cut interest rates. The the Political Bureau of the Communist Party of China (CPC) Central Committee meeting held on December 9 changed the orientation of monetary policy from "steady" to "moderate easing" next year. Experts said that under the orientation of "moderate easing", the monetary policy space was further opened. In terms of total amount, it is more reasonable and sufficient to maintain liquidity; In terms of price, appropriately reducing the financing cost will better reflect the effectiveness of monetary policy. Next year, even greater RRR cuts and interest rate cuts can be expected. In addition to lowering the RRR and cutting interest rates, experts said that structural monetary policy tools, buying government bonds, open market buyout reverse repurchase and other operations are expected to continue to expand the scale, increase the frequency of use, and continuously enhance the effectiveness and pertinence of monetary policy. (CSI)The commander of Syrian democratic forces said that under the mediation of the US, Syrian rebels and Syrian democratic forces reached a ceasefire agreement in the northern city of Mambiji.

Ministry of Finance of Korea: Korea's financial market is still facing uncertainty.Oppenheimer: Raise the target price of opening customers from $980 to $1,075, and reiterate the rating of "outperforming the market".Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.